Organic & Biomolecular Chemistry

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: K. C. K. Swamy and M. Nagarjuna Reddy, *Org. Biomol. Chem.*, 2013, DOI: 10.1039/C3OB41332B.





This is an *Accepted Manuscript*, which has been through the RSC Publishing peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, which is prior to technical editing, formatting and proof reading. This free service from RSC Publishing allows authors to make their results available to the community, in citable form, before publication of the edited article. This *Accepted Manuscript* will be replaced by the edited and formatted *Advance Article* as soon as this is available.

To cite this manuscript please use its permanent Digital Object Identifier (DOI®), which is identical for all formats of publication.

More information about *Accepted Manuscripts* can be found in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics contained in the manuscript submitted by the author(s) which may alter content, and that the standard **Terms & Conditions** and the **ethical guidelines** that apply to the journal are still applicable. In no event shall the RSC be held responsible for any errors or omissions in these *Accepted Manuscript* manuscripts or any consequences arising from the use of any information contained in them.

RSCPublishing

www.rsc.org/obc Registered Charity Number 207890



ARTICLE TYPE

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxx

Dual catalysis by Cu(I): Facile single step click and intramolecular C-O bond formation leading to triazole tethered dihydrobenzodioxines/ benzoxazines/ benzoxathiines/ benzodioxepines

M. Nagarjuna Reddy^a and K. C. Kumara Swamy^{*a}

s Received (in XXX, XXX) Xth XXXXXXXX 20XX, Accepted Xth XXXXXXXX 20XX DOI: 10.1039/b000000x

Dual copper catalysis, involving two different reactions, click (alkyne-azide) and carbon-oxygen bond formation (aryl iodide-secondary alcohol) in a single step, is reported. Synthesis of novel benzodioxines (benzodioxanes), benzoxazines, benzoxathiines and which feature benzo-condensed six or seven ¹⁰ membered rings containing two hetero-atoms attached to a 1,2,3-triazole, is described. As an extension, such compounds were also synthesised by the ring opening of epoxide and cyclisation using Cu(I). All the key products have been characterized by single crystal X-ray crystallography.

Introduction

Published on 30 July 2013. Downloaded by University of Glasgow Library on 31/07/2013 11:31:11.

Among the copper catalysed reactions, the most promising atom ¹⁵ economy reaction in the current scenario is the click reaction between alkynes and organic azides leading to triazoles because of the potential use of the products, ranging from medicinal chemistry to materials science.¹⁻² In the last few years, copper catalysts are also extensively utilized in the construction of C-X ²⁰ (X = N, S, O, P) bond³ with aryl halides as coupling partners. Hartwig and Buchwald reported the palladium catalyzed reactions with alcohols and aryl halide.⁴ The main drawback in the palladium catalyzed reactions is the limited number of ligands and possibility of β-hydrogen elimination in secondary alcohols.

- ²⁵ As a result, copper catalysis is utilized in constructing carbonoxygen⁵ bond with secondary alcohol and arylhalides.⁶ Research is focusing towards one-pot reactions to reduce wastage of chemicals, time and for its economical value.⁷ Literature survey revealed that such one pot synthesis of dihydro-benzodioxine,
- ³⁰ benzoxazine and benzoxathiine having 1,2,3-triazole analogues is not reported till date. Benzo-condensed six membered heterocyclic compounds containing two heteroatoms have wide applications in medicinal chemistry.⁸ Among these, benzodioxine (e.g., domoxin, piperoxan, eltoprazine, fluparoxan,
- ³⁵ idazoxan, prosympal) and benzoxathiine core structure are found in a variety of pharmaceutically useful (e.g., α -adrenergic blockers,^{8g} estrogenic agent^{8h}) compounds. We believe that derivatisation on these heterocycles will have substantial benefits in medicinal chemistry and hence are interested in constructing
- ⁴⁰ both these apparently-simple looking heterocyclic rings, with a variety of substituents.

As a part of our ongoing research into the transition-metalcatalyzed C-C, C-N and C-O bond forming reactions,⁹ we planned to synthesise heterocyclic moieties tethered with triazole ⁴⁵ moiety. Recently, we showed a simple method for the one pot sequential, copper-catalyzed click reaction and intramolecular direct arylation of triazoles thus formed.¹⁰ In continuation of this work, we intended to construct benzo-dioxine, -oxazine,-oxathine and -dioxepine heterocyclic ring utilizing atom ⁵⁰ economical copper-catalysed click reaction and C-O bond formation in one-pot. The results in which Cu(I) species plays the role of a 'dual catalyst' are reported herein.

Results and Discussion

Generation of the required starting materials **2a-l** was ⁵⁵ accomplished as shown in Scheme **1**; details of experimental data for these substrates are given in the supplementary material. Published on 30 July 2013. Downloaded by University of Glasgow Library on 31/07/2013 11:31:11



Initial experiments were performed on 1-azido-3-(2s iodophenoxy)propan-2-ol **2a** and phenylacetylene in the presence of copper(I) iodide (10 mol %) and caesium carbonate (3 equiv) in toluene at 120 °C/ 12 h to effect click reaction and intramolecular C-O bond formation. This procedure afforded the triazole linked dihydrobenzodioxine **3** in 55% yield (Scheme **2**).



Conditions: Cul (10 mol %)/ Cs_2CO_3 (3.0 equiv)/ Toluene/ 120 °C/ 12 h Scheme 2

Our next step was directed toward searching the best condition to maximize the yield of compound **3** by screening various reaction parameters as depicted in Table 1. Among the ligands ¹⁵ employed for screening, bipyridine and picolinic acid proved to be promising in obtaining the compound **3** in good yield (Table 1, entries 5, 6), however, we selected to use picolinic acid as it is economically attractive and biocompatible. Other ligands employed were ineffective in increasing the yield. Then the effect ²⁰ of copper salts and base were examined (entries 7-10), they afforded lower yields. As a solvent, toluene was the best when compared to DMF, PEG-400 or water. In the case of diethyl carbonate as solvent, elimination product **5** was isolated along with 1,3-dipolar cyclised product **4** and the expected ²⁵ benzodioxine was not observed.

able 1. Optimization of the reaction conditions for the synthesis of 5					
Entr y	CuX	Ligand	Base	Solvent	Yield (%) ^b
1	CuI		Cs ₂ CO ₃	Toluene	55°
2	CuI	DMEDA	Cs_2CO_3	Toluene	62
3	CuI	L-Proline	Cs ₂ CO ₃	Toluene	49
4	CuI	8-Hydroxy-	Cs_2CO_3	Toluene	55
5	CuI	Bipyridine	Cs ₂ CO ₃	Toluene	75
6	CuI	Picolinic	Cs ₂ CO ₃	Toluene	89
7	CuBr	Picolinic acid	Cs ₂ CO ₃	Toluene	71
8	CuCl	Picolinic acid	Cs ₂ CO ₃	Toluene	66
9	Cu ₂ O	Picolinic acid	Cs_2CO_3	Toluene	48
10	CuI	Picolinic acid	K_2CO_3	Toluene	51
11	CuI	Picolinic acid	Cs_2CO_3	Water	25°
12	CuI	Picolinic acid	Cs_2CO_3	PEG-400	37°
13	CuI	Picolinic acid	Cs ₂ CO ₃	Et_2CO_3	41 ^d
14	CuI	Picolinic acid	Cs ₂ CO ₃	DMF	55

^aQuantities used: 2a (0.5 mmol), phenylacetylene (0.55 mmol), CuX (10 mol%), ligand (20 mol%), base (3.0 equiv), Toluene (1 mL) at 120 °C (oil 30 bath temperature).
^bisolated yields. ^ctriazole 4 was remained (entry 1 - 30%; entry 11 - 50%; entry 12 - 37%).



With the optimized conditions (entry 6, Table 1) in hand, we conducted the reactions of various terminal acetylenes with 2a for 35 the synthesis of triazole based benzodioxine derivatives (Scheme 3). Both electron releasing and withdrawing groups on acetylene afforded triazole benzodioxane (6-14) in good yields, the method worked well for naphthyl, vinyl and aliphatic alkynes also. Activated alkynes also afforded good yield when reacted with ⁴⁰ substrate **2a**. To further explore the efficacy and generality of the method, reactions using different substituted 1-azido-3-(2iodobenzyloxy)-propan-2-ol (2b-e) were investigated for this one-pot reaction to synthesise products 15-18 in good yields. Though two different kinds of reaction were performed in a 45 single step, the yields (isolated) obtained were good in most cases. All the compounds were characterised by IR, NMR and HRMS and the structure of compound 16 was confirmed by Xray crystallography (Figure 1).



Conditions: Cul (10 mol %)/ Picolinic acid (20 mol %)/ Cs₂CO₃ (3.0 equiv)/ Toluene/ 120 °C/ 12 h

Scheme 3

Published on 30 July 2013. Downloaded by University of Glasgow Library on 31/07/2013 11:31:11



Figure 1. ORTEP diagram of compound **16**. Selected bond lengths [Å] 5 with esd's in parentheses: C6-O2 1.376 (4) C8-O2 1.438 (4) N1-N2 1.338(4) N3-N2 1.314(4).

After synthesizing various substituted triazole based benzodioxine derivatives successfully, we planned to extend this methodology to benzoxazines and benzoxathiine based triazoles, ¹⁰ as these moieties also have the same importance as that of benzodioxine derivatives. To achieve this, we prepared substrates **2f**, **2g** and **2h** from 2-iodoaniline and 2-iodothiophenol respectively as shown in Scheme **1** above. These substrates were reacted with phenyl, vinyl and aliphatic alkynes under the ¹⁵ optimized conditions to furnish the expected triazole based benzoxazines (**19-24**) and benzoxathiines (**25-27**) in good yields (Scheme 4). Precursors **2f** and **2g** showed multiple peaks in NMR data due to the possibility of rotamers,¹¹ after cyclisation, the observed NMR data was as expected. The structure of compound





Conditions: Cul (10 mol %)/ Picolinic acid (20 mol %)/ Cs₂CO₃ (3.0 equiv)/ Toluene/ 120 °C/ 12 h Scheme 4



Figure 2. ORTEP diagram of compound 20. Selected bond lengths [Å] with esd's in parentheses: C1-O1 1.366 (4) C8-O1 1.423 (3) N2-N3 25 1.335(4) N3-N4 1.303(4).

Till this point, we were successful in synthesising benzodioxines, benzoxazines and benzoxathiine derivatives. To expand this methodology, we made an effort to synthesise seven membered ring containing compounds also. To achieve this, ³⁰ substrate **2i** was prepared in two steps from 2-iodobenzyl alcohol and epichlorohydrin. Following the optimized condition, we conducted reaction between **2i** and terminal acetylenes which afforded triazole based benzodioxepine derivatives **28-31** in good yields. In this case also, gratifyingly, we were able to construct ³⁵ three new bonds in a single step involving click reaction and intramolecular C-O bond between secondary alcohol and aryl iodide. The structure of compound **30** was confirmed by X-ray crystallography (Figure **3**).



Conditions: Cul (10 mol %)/ Picolinic acid (20 mol %)/ Cs2CO3 (3.0 equiv)/ Toluene/ 120 °C/ 12 h

Scheme 5



Figure 3. ORTEP diagram of compound 30. Selected bond lengths [Å] 5 with esd's in parentheses: C1-O1 1.381 (3) C9-O1 1.442 (2) N1-N2 1.341(3) N3-N2 1.310(3).

In a manner similar to above, we attempted to synthesise seven membered sultam moieties from 2j. Precursor 2j was synthesised from 4-methyl-2-iodo-sulfonamide and epichlorohydrin. Later, 10 we performed reaction between 2j and phenylacetylene in an effort to obtain seven membered sultam derivatives. To our surprise, this reaction led to the ring opened product 32 as shown in Scheme 6. This product arises due to the abstraction of proton from CH₂ moiety adjacent to N and subsequent migration giving 15 the *phenolic* derivative 32. In our previous paper, under base mediated condition, we reported this kind of elimination and another group also reported this kind of phenol derivative from thiaflavans recently.^{10,12} The structure of compound 32 was confirmed by X-ray crystallography (Figure 4).

20

Published on 30 July 2013. Downloaded by University of Glasgow Library on 31/07/2013 11:31:11



Conditions: Cul (10 mol %)/ Picolinic acid (20 mol %)/ Cs2CO3 (3.0 equiv)/ Toluene/ 120 °C/ 12 h





Figure 4. ORTEP diagram of compound 32. Selected bond lengths [Å] 25 with esd's in parentheses: C6-O3 1.353 (2) C7-C8 1.320 (2) N1-N3 1.313(2) N3-N2 1.326(2).

Thus copper catalyzed one-pot click reaction and intramolecular C-O bond formation was successfully employed 30 on aryl halide precursors. We then wondered whether our methodology is applicable to make a carbon-oxygen bond between vinyl iodide and alcohol or not. To achieve this, substrate 2k was prepared from 2-iodo-cyclohexenol and 3chloro-2-epoxy propane (Scheme 1). Later, substrate 2k was 35 subjected to optimized condition with terminal acetylenes to obtain 1,4-dioxine ring products. Substrate 2k has two chiral centres, which shows a possibility of four stereoisomers. The presence of two sets of equal intensity peaks in the ¹H and ¹³C NMR of these compounds suggests the presence of diastereomers 40 in 1:1 ratio. Satisfyingly, though, the reaction does work efficiently in this case also.



Conditions: Cul (10 mol %)/ Picolinic acid (20 mol %)/ Cs2CO3 (3.0 equiv)/ Toluene/ 120 °C/ 12 h

Scheme 7

In general, it is expected that the aryl bromides are less reactive 45 than aryl iodides in reactions such as those described above. In line with this, the reaction between bromo precursor 21 and phenylacetylene utilizing the optimized condition described above afforded the expected benzodioxine 3 along with the uncyclised product 36 (Scheme 8). Thus, under these conditions, 50 coupling of aryl/vinyl iodides are more successful than of aryl bromides towards a secondary alcohol.



Conditions: Cul (10 mol %)/ Picolinic acid (20 mol %)/ Cs₂CO₃ (3.0 equiv)/Toluene/ 120 °C/ 24 h

Scheme 8

After utilising [Cu]-catalysis successfully in two mechanistically different reactions to construct triazole appended benzodioxines/benzoxazines, we envisioned to synthesise such ⁵ derivatives starting from the epoxide **1**. There are only a handful of reports available related to ring opening of epoxides/aziridines and further cyclisation by copper-catalysis to obtain the benzodioxines/benzoxazine/benzothiines.6 Thus, in a one-pot procedure starting from the epoxides (1a, 1b, 1d, 1f) the triazole 10 fused benzodioxines (37-39) and benzoxazine (40) were obtained in good yield. This reaction involves the ring opening of epoxide by benzotriazole and intramolecular cyclisation forming a new C-O bond (Scheme 9). The intermediate 41 could be readily isolated by the reaction of benzotriazole with the epoxide 1a under neat 15 conditions at 100 °C.



Conditions: (i) 100 °C 1h then Cul (10 mol %)/ Picolinic acid (20 mol %)/ Cs_2CO_3 (3.0 equiv)/Toluene/ 120 °C/ 12 h



Scheme 9

Published on 30 July 2013. Downloaded by University of Glasgow Library on 31/07/2013 11:31:11

A possible pathway for the above sequential click reaction and intramolecular cyclisation involves two steps. First step involves the formation of 1,2,3-triazole from alkyne and azide *via* a ²⁰ dinuclear copper intermediate.^{1d} This pathway is supported by a very recent paper of Worrell¹³ *et al*. The second step involves the formation of C-O bond; here, we performed a series of reactions starting from **4** (Scheme 10) to check the effect of different conditions. There was no reaction when base (condition **a**) or ²⁵ copper catalyst (condition **b**) was absent. Notably, product **3** was observed in 62% of yield without addition of ligand (condition **c**) and in one-pot strategy we obtained 55% yield (cf. Scheme 1 above). In this case, the triazole and OH moieties act as bidentate ligand (similar to hydroxymethyl benzotriazole which is used in ³⁰ copper-catalysis¹⁴ as a ligand). To achieve good yields in this methodology copper/ligand/base are required.



There are two plausible pathways¹⁵⁻¹⁶ to explain the etherification step: (i) involves the oxidative addition of copper(I) source across ³⁵ C-X bond generating Cu(III) intermediate **A**, followed by replacement of X with the nucleophile in the presence of base forming complex **B**, or (ii) nucleophile reacts with Cu(I) source to form complex **C**¹⁶ and further oxidative addition onto C-X bond leading to complex **B**. In both these pathways, reductive ⁴⁰ elimination^{16c} is the final step affording the desired product **3**. Cs₂CO₃ acts as a base and picolinic acid (or picolinate) acts as the ligand (L). Recent reports favour the second mechanism.¹⁶



T = triazole; L = picolinic acid (picolinate)

Chart 1

45 Conclusion

We have successfully demonstrated a simple *one-pot* synthesis of 1,2,3-triazole appended benzodioxines (benzodioxanes), benzoxazines and benzoxathiine. The involvement of two different kinds of reaction, *a click and an intramolecular so carbon-oxygen bond formation using Cu(I) dual catalytic system*, should make this method appealing to synthetic chemists. These compounds were also synthesised by the ring opening of epoxide and cyclisaiton using Cu(I). The wide applicability is also amply proven by the diverse range of substrates used. 55 Finally, we have shown that this method is applicable to both aryl and vinyl iodide reactants and reaction with aryl bromides is sluggish.

Experimental Section

The general experimental conditions and synthesis of the 60 precursors are described in the supplementary material.

General Procedure

An oven-dried Schlenk tube with a magnetic stirring bar was charged with CuI (10 mol%), picolinic acid (20 mol%), cesium carbonate (3.0 equiv), and toluene (1 mL) under nitrogen

atmosphere. Later, 1-azido-3-(2-iodophenoxy)propan-2-ol (**2a**, 0.5 mmol) and phenyl acetylene (0.55 mmol) were added *via* syringe, and the contents heated at 120 °C (oil bath temperature) for 12 h. The mixture was then cooled to ambient temperature, s diluted with 2-3 mL of ethyl acetate, passed through a plug of celite, and then washed with 20-30 mL of ethyl acetate. The organic layer was evaporated and the residue purified by column chromatography on silica gel by using hexane/ethyl acetate (75/25) as eluent to afford the desired product **3**. Compounds **6**-

- ¹⁰ **32** were obtained using the same molar quantities in all the cases. **Compound 3:** Yield 0.130 g (89%); mp 118-120 °C; IR (KBr, cm⁻¹) 3084, 1595, 1499, 1277, 1204, 1046, 766; ¹H NMR (400 MHz, CDCl₃) δ 7.89 (s, 1H, triazole-*H*), 7.85 (dd, *J* ~ 8.0 and 1.2 Hz, 2H, Ar-*H*), 7.44 (t, *J* ~ 8.0 Hz, 2H, Ar-*H*), 7.34-7.37 (m, 1H, 15 Ar-*H*), 6.88-6.94 (m, 4H, Ar-*H*), 4.72-4.75 (m, 2H, CH₂), 4.66-4.69 (m, 1H, OC*H*), 4.37 (dd, *J* = 11.6 and 2.0 Hz, 1H, CH_aH_b), 3.94 (dd, *J* = 11.6 and 6.0 Hz, 1H, CH_aH_b); ¹³C NMR (100 MHz, CDCl₃) δ 148.1, 142.8, 142.0, 130.4, 128.9, 128.3, 125.8, 122.2, 121.1, 117.5, 71.3 (OCH), 64.9 (OCH₂), 50.2 (NCH₂); HRMS
- ²⁰ (ESI) Calc. for $C_{17}H_{16}N_3O_2$ [M+H]⁺ 294.1243, Found: 294.1245. **Compound 4:** Yield 0.196 g (93%); mp 139-141 °C; IR (KBr, cm⁻¹) 3385, 1582, 1474, 1441, 1281, 1231, 1123, 1047, 760, 739; ¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1H, triazole-*H*), 7.77-7.80 (m, 3H, Ar-*H*), 7.35-7.43 (m, 2H, Ar-*H*), 7.29-7.33 (m, 2H, Ar-*H*), 7.29-7.34 (m, 2H, Ar-*H*),
- ²⁵ *H*), 6.76-6.82 (m, 2H, Ar-*H*), 4.82 (dd, J = 14.0 and 4.0 Hz, 1H, CH_aH_b), 4.71 (dd, J = 14.0 and 6.4 Hz, 1H, CH_aH_b), 4.56-4.58 (m, 1H, CHOH), 4.01-4.08 (m, 2H, CH₂), 3.54 (br s, 1H, OH); ¹³C NMR (100 MHz, CDCl₃) δ 156.4, 147.6, 139.4, 130.2, 129.8, 128.9, 128.3, 125.7, 123.5, 121.5, 112.6, 86.6 (CI), 69.9 (OCH), ³⁰ 68.7 (OCH₂), 53.1 (NCH₂); HRMS (ESI) Calc. for C₁₇H₁₇IN₃O₂

[M+H]⁺ 422.0366, Found: 422.0368. **Compound 5:** Yield 0.045 g (35%); mp 138-140 °C; IR (KBr, cm⁻¹) 3134, 1682, 1573, 1474, 1441, 1277, 1041, 997, 751, 690; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (s, 1H, triazole-*H*), 7.79-7.88

- ³⁵ (m, 3H, Ar-*H*), 7.62-7.65 (m, 1H, Ar-*H*), 7.32-7.47 (m, 4H, Ar-*H*), 6.88 (d, J = 8.4 Hz, 1H, Ar-*H*), 6.77-6.80 (m, 1H, =C-*H*), 6.54-6.59 (m, 1H, =C-*H*), 4.81 (m, 2H, OC*H*₂); ¹³C NMR (100 MHz, CDCl₃) δ 156.6, 148.1, 139.8, 131.7, 130.1, 129.7, 129.0, 126.5, 125.9, 123.5, 117.3, 116.7, 112.6, 86.8 (*C*I), 66.5 (OC*H*₂); ⁴⁰ HRMS (ESI) Calc. for C₁₇H₁₅IN₃O [M+H]⁺ 404.0261, Found:
- 404.0263. **Compound 6:** Yield 0.138 g (85%); mp 116-118 °C; IR (KBr, cm⁻¹) 3115, 2936, 1615, 1561, 1497, 1456, 1362, 1248, 1177, 1103, 1024, 910, 837, 752; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (s,
- ⁴⁵ 1H, triazole-*H*), 7.77 (dd, J = 6.8 and 2.0 Hz, 2H, Ar-*H*), 6.88-6.99 (m, 6H, Ar-*H*), 4.70-4.76 (m, 2H, CH₂), 4.63-4.67 (m, 1H, OC*H*), 4.36 (dd, J = 11.6 and 2.0 Hz, 1H, CH_aH_b), 3.93 (dd, J =11.6 and 6.0 Hz, 1H, CH_aH_b), 3.85 (s, 3H, Ar-OCH₃);¹³C NMR (100 MHz, CDCl₃) δ 159.8, 148.0, 142.9, 142.0, 127.2, 123.1,
- $_{50}$ 122.2, 120.2, 117.6, 117.5, 114.3, 71.4 (OCH), 65.0 (OCH_2), 55.4 (OCH_3), 50.2 (NCH_2); HRMS (ESI) Calc. for $C_{18}H_{18}N_3O_3$ $[M+H]^+$ 324.1349, Found: 324.1347.
- **Compound 7:** Yield 0.134 g (87%); mp 138-140 °C; IR (KBr, cm⁻¹) 3088, 1595, 1499, 1454, 1277, 1204, 1046, 820, 747; ¹H ⁵⁵ NMR (400 MHz, CDCl₃) δ 7.85 (s, 1H, triazole-*H*), 7.73 (d, *J* =
- 8.4 Hz, 2H, Ar-*H*), 7.25 (d, J = 8.4 Hz, 2H, Ar-*H*), 6.89-6.94 (m, 4H, Ar-*H*), 4.71-4.74 (m, 2H, CH₂), 4.67-4.68 (m, 1H, O-CH), 4.37 (dd, J = 11.6 and 2.0 Hz, 1H, CH_aH_b), 3.94 (dd, J = 11.6 and

6.0 Hz, 1H, CH_aH_b), 2.93 (s, 3H, Ar- CH_3); ¹³C NMR (100 MHz, ⁶⁰ CDCl₃) δ 148.3, 142.9, 142.0, 138.3, 129.6, 127.6, 125.8, 122.2, 120.7, 117.6, 71.4 (OCH), 65.0 (OCH₂), 50.2 (NCH₂), 21.4 (CH₃); HRMS (ESI) Calc. for C₁₈H₁₇N₃O₂Na [M+Na]⁺ 330.1219, Found: 330.1218.

- **Compound 8:** Yield 0.139 g (82%); mp 154-156 °C; IR (KBr, ⁶⁵ cm⁻¹) 3086, 1597, 1518, 1501, 1462, 1350, 1279, 1049, 853, 750; ¹H NMR (400 MHz, CDCl₃) δ 8.31 (d, J = 8.8 Hz, 2H, Ar-H), 8.01-8.03 (m, 3H, triazole-H+Ar-H), 6.89-6.95 (m, 4H, Ar-H), 4.68-4.83 (m, 3H, OCH+C H_2), 4.39 (dd, J ~ 11.6 and 2.0 Hz, 1H, CH_a H_b), 3.96 (dd, J ~11.6 and 6.0 Hz, 1H, C H_a H_b); ¹³C NMR
- ⁷⁰ (100 MHz, CDCl₃) δ 147.4, 146.0, 142.7, 141.8, 136.6, 126.3, 124.4, 122.5, 122.3₃, 122.2₇, 117.6, 117.4, 71.2 (OCH), 64.8 (OCH₂), 50.4 (NCH₂); HRMS (ESI) Calc. for C₁₇H₁₅N₄O₄ [M+H]⁺ 339.1094, Found: 339.1092.
- **Compound 9:** Yield 0.128 g (80%); mp 108-110 °C; IR (KBr, 75 cm⁻¹) 3138, 2916, 1688, 1595, 1497, 1466, 1271, 1198, 1109, 1038, 828, 777, 745; ¹H NMR (400 MHz, CDCl₃) δ 10.4 (s, 1H, CHO), 8.04 (d, J = 7.2 Hz, 1H, Ar-H), 7.98 (s, 1H, triazole-H), 7.74 (d, $J \sim 7.2$ Hz, 1H, Ar-H), 7.66-7.70 (m, 1H, Ar-H), 7.54 (t, $J \sim 7.6$ Hz, 1H, Ar-H), 6.89-6.94 (m, 4H, Ar-H), 4.69-4.85 (m,
- ⁸⁰ 3H, OCH+CH₂), 4.40 (dd, J = 11.6 and 2.4 Hz, 1H, CH_aH_b), 3.99 (dd, $J \sim 11.6$ and 6.0 Hz, 1H, CH_aH_b); ¹³C NMR (100 MHz, CDCl₃) δ 192.4, 145.0, 142.8, 141.8, 133.8, 132.7, 130.1, 129.1, 128.8, 124.8, 122.3, 117.6, 117.5, 71.3 (OCH), 64.9 (OCH₂), 50.4 (NCH₂); HRMS (ESI) Calc. for C₁₈H₁₆N₃O₃ [M+H]⁺ 322.1192, 85 Found: 322.1194.
- **Compound 10:** Yield 0.144 g (84%); mp 129-131 °C; IR (KBr, cm⁻¹) 3052, 2912, 1591, 1497, 1466, 1265, 1204, 1119, 1053, 1038, 903, 799, 754; ¹H NMR (400 MHz, CDCl₃) δ 8.36-8.38 (m, 1H, Ar-*H*), 7.95 (s, 1H, triazole-*H*), 7.90-7.93 (m, 2H, Ar-*H*),
- ⁹⁰ 7.75 (d, J = 7.2 Hz, 1H, Ar-*H*), 7.51-7.56 (m, 3H, Ar-*H*), 6.89-6.95 (m, 4H, Ar-*H*), 4.77-4.85 (m, 2H, CH₂), 4.71-4.74 (m, 1H, OC-*H*), 4.41 (dd, J = 11.6 and 2.0 Hz, 1H, CH_aH_b), 4.01 (dd, J =11.6 and 6.0 Hz, 1H, CH_aH_b); ¹³C NMR (100 MHz, CDCl₃) δ 147.2, 142.9, 142.0, 134.0, 131.2, 129.1, 128.6, 127.9, 127.4, 126.8, 126.1, 125.4, 125.2, 124.1, 122.2, 117.6, 117.5, 71.5
- $_{95}$ 126.8, 126.1, 125.4₂, 125.3₇, 124.1, 122.2, 117.6, 117.5, 71.5 (OCH), 65.0 (OCH₂), 50.3 (NCH₂); HRMS (ESI) Calc. for $C_{21}H_{18}N_3O_2 \ [M+H]^+$ 344.1400, Found: 344.1398.

Compound 11: Yield 0.168 g (75%); mp 102-104 °C; IR (KBr, cm⁻¹) 3167, 2922, 1593, 1495, 1458, 1437, 1260, 1217, 1123, 100 1051, 1019, 928, 828, 747; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (s,

- ¹⁰⁰ 1051, 1019, 928, 828, 747; H NMR (400 MHz, CDCl₃) ∂ 7.85 (s, 1H, triazole-*H*), 7.77 (dd, *J* = 8.0 and 1.6 Hz, 1H, Ar-*H*), 7.29-7.33 (m, 1H, Ar-*H*), 6.98 (d, *J* = 8.0 Hz, 1H, Ar-*H*), 6.89 (br, 4H, Ar-*H*), 6.72-6.76 (m, 1H, Ar-*H*), 5.32 (s, 2H, OCH₂), 4.60-4.72 (m, 3H, OCH + CH₂), 4.34 (dd, *J* ~ 11.6 and 2.0 Hz, 1H, CH_aH_b),
- ¹⁰⁵ 3.89 (dd, J = 11.6 and 6.0 Hz, 1H, CH_aH_b); ¹³C NMR (100 MHz, CDCl₃) δ 156.7, 144.5, 142.8, 141.8, 139.6, 129.7, 124.4, 123.3, 122.2, 122.1, 117.6, 117.5, 112.9, 86.8 (CI), 71.3 (OCH), 64.9 (OCH₂), 63.6 (OCH₂), 50.2 (NCH₂); HRMS (ESI) Calc. for C₁₈H₁₇IN₃O₃ [M+H]⁺ 450.0315, Found: 450.0317.
- ¹¹⁰ **Compound 12:** Yield 0.127 g (79%); mp 149-151 °C; IR (KBr, cm⁻¹) 3129, 2924, 1645, 1595, 1526, 1493, 1254, 1080, 905, 829, 752; ¹H NMR (400 MHz, CDCl₃) δ 8.41-8.44 (m, 2H, Ar-*H*), 8.39 (s, 1H, triazole-*H*), 7.61-7.65 (m, 1H, Ar-*H*), 7.52-7.56 (m, 2H, Ar-*H*), 6.89-6.95 (m, 4H, Ar-*H*), 4.67-4.85 (m, 3H, OCH +
- ¹¹⁵ CH₂), 4.39 (dd, $J \sim 11.6$ and 2.0 Hz, 1H, CH_aH_b), 3.98 (dd, J = 11.6 and 6.0 Hz, 1H, CH_aH_b); ¹³C NMR (100 MHz, CDCl₃) δ

185.7, 148.4, 142.7, 141.7, 136.5, 133.5, 130.7, 129.9, 128.5, 122.4, 117.7, 117.6, 71.1 (OCH), 64.8 (OCH₂), 50.5 (NCH₂); HRMS (ESI) Calc. for $C_{18}H_{16}N_3O_3$ [M+H]⁺ 322.1192, Found: 322.1189.

- ⁵ **Compound 13:** Yield 0.116 g (78%); mp 106-108 °C; IR (KBr, cm⁻¹) 3156, 3044, 2924, 1593, 1497, 1462, 1298, 1269, 1051, 1036, 905, 839, 750; ¹H NMR (400 MHz, CDCl₃) δ 7.52 (s, 1H, triazole-*H*), 6.88-6.92 (m, 4H, Ar-*H*), 6.83-6.54 (m, 1H, alkene-*H*), 4.59-4.67 (m, 3H, OC*H* + *CH*₂), 4.32 (dd, *J* ~ 11.6 and 2.0
- ¹⁰ Hz, 1H, CH_a*H*_b), 3.87 (dd, *J* = 11.6 and 6.0 Hz, 1H, C*H*_aH_b), 2.28-2.41 (m, 2H, C*H*₂), 2.20-2.23 (m, 2H, C*H*₂), 1.66-1.79 (m, 4H, 2 C*H*₂); ¹³C NMR (100 MHz, CDCl₃) δ 149.8, 142.8, 142.0, 127.1, 125.4, 122.0, 119.7, 117.4, 71.4 (OCH), 64.9 (OCH₂), 50.0 (NCH₂), 26.4, 25.3, 22.4, 22.2; HRMS (ESI) Calc. for ¹⁵ C₁₇H₂₀N₃O₂ [M+H]⁺ 298.1556, Found: 298.1554.
- **Compound 14:** Yield 0.118 g (72%); mp 75-77 °C; IR (KBr, cm⁻¹) 3063, 2924, 2851, 1597, 1501, 1464, 1279, 1053, 862, 743; ¹H NMR (400 MHz, CDCl₃) δ 7.40 (s, 1H, triazole-*H*), 6.89-6.92 (m, 4H, Ar-*H*), 4.63-4.66 (m, 2H, CH₂), 4.58-4.61 (m, 1H, OC*H*),
- ²⁰ 4.32 (dd, J = 11.6 and 2.0 Hz, 1H, CH_aH_b), 3.87 (dd, J = 11.6 and 6.0 Hz, 1H, CH_aH_b), 2.72 (t, J = 6.8 Hz, 2H, CH₂), 1.66-1.69 (m, 2H, CH₂), 1.27-1.33 (m, 10H, 5 CH₂), 0.88 (t, J = 6.6 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃) δ 148.9, 142.9, 142.1, 122.1, 122.0, 117.5, 117.4, 71.5 (OCH), 65.0 (OCH₂), 50.0 (NCH₂), ²⁵ 31.9, 29.5, 29.4, 29.3, 25.7, 22.7, 14.2 (CH₃); HRMS (ESI) Calc.
- for C₁₉H₂₈N₃O₂ [M+H]⁺ 330.2182 Found: 330.2178. **Compound 15:** Yield 0.139 g (81%); mp 148-150 °C; IR (KBr, cm⁻¹) 3083, 1634, 1603, 1474, 1395, 1358, 1260, 1105, 1051, 978, 808, 768, 693; ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* =
- ³⁰ 8.4 Hz, 1H, Ar-*H*), 7.84 (s, 1H, triazole-*H*), 7.78-7.83 (m, 3H, Ar-*H*), 7.45-7.52 (m, 1H, Ar-*H*), 7.40-7.45 (m, 4H, Ar-*H*), 7.33-7.37 (m, 1H, Ar-*H*), 7.13 (dd, $J \sim 8.4$ and 2.8 Hz, 1H, Ar-*H*), 4.78-4.88 (m, 3H, OC*H* + C*H*₂), 4.48 (dd, $J \sim 11.6$ and 2.0 Hz, 1H, CH_aH_b), 4.12 (dd, J = 11.6 and 4.8 Hz, 1H, CH_aH_b); ¹³C
- $_{35}$ NMR (100 MHz, CDCl₃) δ 148.2, 138.4, 134.6, 130.4, 129.9, 129.0, 128.4, 127.9, 126.3, 125.8, 125.5, 124.7, 121.9, 121.1, 119.8, 118.3, 71.6 (OCH), 65.0 (OCH₂), 50.1 (NCH₂); HRMS (ESI) Calc. for C₂₁H₁₇N₃O₂Na [M+Na]⁺ 366.1219, Found: 366.1217.
- ⁴⁰ **Compound 16:** Yield 0.134 g (82%); mp 137-140 °C; IR (KBr, cm⁻¹) 3094, 2924, 1588, 1493, 1462, 1275, 1200, 1084, 1038, 936, 856, 766, 693; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (s, 1H, triazole-*H*), 7.84 (d, *J* = 8.0 Hz, 2H, Ar-*H*), 7.45 (t, *J* ~ 7.4 Hz, 2H, Ar-*H*), 7.36 (t, *J* ~ 7.4 Hz, 1H, Ar-*H*), 6.93-6.94 (m, 1H, Ar-
- ⁴⁵ *H*), 6.82-6.88 (m, 2H, Ar-*H*), 4.64-4.73 (m, 3H, OC*H* + C*H*₂), 4.36 (dd, $J \sim 11.6$ and 2.0 Hz, 1H, CH_aH_b), 3.91 (dd, $J \sim 11.6$ and 6.0 Hz, 1H, CH_aH_b); ¹³C NMR (100 MHz, CDCl₃) δ 148.3, 142.5, 141.6, 130.3, 129.0, 128.5, 126.7, 125.9, 122.2, 121.0, 118.4, 117.6, 71.6 (OCH), 64.9 (OCH₂), 50.1 (NCH₂); HRMS (ESI)
- $_{50}$ Calc. for $C_{17}H_{15}ClN_3O_2~[M+H]^+$ 328.0854 and 330.0824, Found: 328.0853 and 330.0817. This compound was crystallized from dichloromethane/hexane (1:1) mixture at 25 °C. X-ray structure was determined for this compound.

Compound 17: Yield 0.150 g (86%); mp 166-169 °C; IR (KBr, ⁵⁵ cm⁻¹) 3092, 2963, 1582, 1503, 1466, 1310, 1269, 1231, 1088, 1073, 918, 764; ¹H NMR (400 MHz, CDCl₃) δ 7.91 (s, 1H, triazole-*H*), 7.85 (dd, *J* = 8.4 and 1.2 Hz, 2H, Ar-*H*), 7.45 (t, *J* ~ 7.4 Hz, 2H, Ar-*H*), 7.36 (t, *J* ~ 7.4 Hz, 1H, Ar-*H*), 6.91-6.95 (m,

2H, Ar-*H*), 6.84 (d, J = 8.4 Hz, 1H, Ar-*H*), 4.63-4.74 (m, 3H, 60 OC*H* + C*H*₂), 4.34 (dd, J = 11.6 and 2.0 Hz, 1H, CH_a*H*_b), 3.90 (dd, J = 11.6 and 6.4 Hz, 1H, C*H*_aH_b), 1.29 (s, 9H, C(C*H*₃)₃); ¹³C NMR (100 MHz, CDCl₃) δ 148.2, 145.7, 141.4, 140.4, 130.5, 129.0, 128.4, 125.9, 121.1, 119.2, 116.9, 114.4, 71.5 (OCH), 65.0 (OCH₂), 50.4 (NCH₂), 34.4, 31.5; HRMS (ESI) Calc. for

⁶⁵ C₂₁H₂₄N₃O₂ [M+H]⁺ 350.1869, Found: 350.1867. **Compound 18:** Yield 0.134 g (78%); mp 126-128 °C; IR (KBr, cm⁻¹) 3127, 2922, 1603, 1499, 1439, 1318, 1217, 1074, 1028, 859, 766, 693; ¹H NMR (400 MHz, CDCl₃) δ 7.89 (s, 1H, triazole-*H*), 7.84-7.86 (m, 2H, Ar-*H*), 7.35-7.46 (m, 3H, Ar-*H*), 70 6.58-6.59 (m, 2H, Ar-*H*), 4.61-4.74 (m, 3H, OC*H* + C*H*₂), 4.35 (dd, *J* = 11.6 and 2.0 Hz, 1H, CH_aH_b), 3.93 (dd, *J* = 11.6 and 6.0 Hz, 1H, CH_aH_b), 2.17 and 2.24 (2 s, 6H, 2 CH₃); ¹³C NMR (100 MHz, CDCl₃) δ 148.1, 141.3, 138.7, 130.9, 130.4, 128.9, 128.3, 126.7, 125.8, 124.2, 121.1, 115.2, 71.3 (OCH), 64.9 (OCH₂), 50.3

⁷⁵ (NCH₂), 20.7 and 15.4 (2 CH₃); HRMS (ESI) Calc. for $C_{19}H_{19}N_3O_2Na$ [M+Na]⁺ 344.1375, Found: 344.1377.

Compound 19: Yield 0.192 g (86%); mp 163-165 °C; IR (KBr, cm⁻¹) 3136, 2918, 1588, 1480, 1449, 1340, 1242, 1159, 1066, 910, 848, 760; ¹H NMR (400 MHz, CDCl₃) δ 7.82-7.84 (m, 2H, cm⁻¹) 7.81 (s, 1H triazole H) 7.78 (dd L = 2.4 and 1.6 Uz, 1H

⁸⁰ Ar-*H*), 7.81 (s, 1H, triazole-*H*), 7.78 (dd, *J* = 8.4 and 1.6 Hz, 1H, Ar-*H*), 7.52 (d, *J* = 8.0 Hz, 2H, Ar-*H*), 7.44 (t, *J* ~ 7.6 Hz, 2H, Ar-*H*), 7.35 (t, *J* ~ 7.6 Hz, 1H, Ar-*H*), 7.22 (d, *J* = 8.4 Hz, 2H, Ar-*H*), 7.08 (t, *J* = 7.2 Hz, 1H, Ar-*H*), 6.96 (t, *J* = 7.2 Hz, 1H, Ar-*H*), 6.87 (dd, *J* ~ 8.4 and 1.2 Hz, 1H, Ar-*H*), 4.60 (d, *J* = 4.8 Hz, 85 2H, NCH₂), 4.33 (dd, *J* = 14.4 and 2.4 Hz, 1H, NCH₂H_b), 3.83-

⁸⁵ 2H, NCH₂), 4.55 (dd, J = 14.4 and 2.4 Hz, 1H, NCH_aH_b), 3.83-3.89 (m, 1H, OCH), 3.14 (dd, J = 14.4 and 9.6 Hz, 1H, NCH_aH_b), 2.37 (s, 3H, ArCH₃); ¹³C NMR (100 MHz, CDCl₃) δ 148.1, 145.9, 144.7, 135.3, 130.3, 130.2, 129.0, 128.5, 127.2, 126.4, 125.8, 124.4, 123.5, 121.7, 120.9, 117.4, 70.3 (OCH), 51.4 90 (NCH₂), 45.8 (NCH₂), 21.7 (ArCH₃); HRMS (ESI) Calc. for C H N O S IM₄H⁺ 447.1402 Found: 447.1480

- C₂₄H₂₃N₄O₃S [M+H]⁺ 447.1492. Found: 447.1489. Compound 20: Yield 0.173 g (77%); mp 168-170 °C; IR (KBr, cm⁻¹) 3134, 2920, 1655, 1584, 1479, 1447, 1342, 1238, 1167, 1068, 942, 856, 762, 657, 564; ¹H NMR (400 MHz, CDCl₃) δ 95 7.76 (d, J ~ 8.0 Hz, 1H, Ar-H), 7.48 (d, J = 8.0 Hz, 2H, Ar-H), 7.43 (s, 1H, triazole-H), 7.22 (d, J ~ 8.0 Hz, 2H, Ar-H), 7.07 (t, J ~ 7.6 Hz, 1H, Ar-H), 6.95 (t, J = 7.6 Hz, 1H, Ar-H), 6.84 (d, J = 8.0 Hz, 1H, Ar-H), 6.52 (s, 1H, cyclohexenyl-H), 4.51 (d, J = 4.8 Hz, 2H, NCH₂), 4.29 (dd, $J \sim 14.4$ and 2.4 Hz, 1H, NCH_aH_b), 100 3.75-3.77 (m, 1H, OCH), 3.05 (dd, J = 14.4 and 9.6 Hz, 1H, NCH_aH_b), 2.38 (br s, 5H, CH₂+ArCH₃), 2.19-2.20 (m, 2H, CH₂), 1.65-1.78 (m, 4H, 2 CH₂); ¹³C NMR (100 MHz, CDCl₃) δ 149.8, 145.9, 144.6, 135.2, 130.1, 127.2, 127.0, 126.3, 125.5, 124.4, 123.4, 121.6, 119.6, 117.4, 70.2 (OCH), 51.2 (NCH₂), 45.7 105 (NCH₂), 26.4, 25.3, 22.4, 22.2, 21.6 (ArCH₃); HRMS (ESI) Calc. for C₂₄H₂₇N₄O₃S [M+H]⁺ 451.1805, Found: 451.1806. This compound was crystallized from dichloromethane/hexane (2:1) mixture at 25 °C. X-ray structure was determined for this
- compound. **110 Compound 21:** Yield 0.183 g (76%); mp 68-70 °C; IR (KBr, cm⁻¹) 3162, 2915, 2849, 1594, 1479, 1449, 1348, 1233, 1162, 1068, 926, 800, 762, 663, 575; ¹H NMR (400 MHz, CDCl₃) δ 7.77 (dd, $J \sim 8.0$ and 1.6 Hz, 1H, Ar-*H*), 7.50 (d, J = 8.4 Hz, 2H, Ar-*H*), 7.32 (s, 1H, triazole-*H*), 7.24 (d, J = 8.4 Hz, 2H, Ar-*H*), 7.05-7.09 **115** (m, 1H, Ar-*H*), 6.93-6.97 (m, 1H, Ar-*H*), 6.84 (dd, J = 8.0 and
- 1.2 Hz, 1H, Ar-H), 0.55-0.57 (iii, 1H, Ai-H), 0.84 (idi, J = 8.0 and 1.2 Hz, 1H, Ar-H), 4.50 (d, J = 4.8 Hz, 2H, NCH₂), 4.28 (dd, J =

Published on 30 July 2013. Downloaded by University of Glasgow Library on 31/07/2013 11:31:11

14.4 and 2.4 Hz, 1H, NCH_aH_b), 3.81-3.85 (m, 1H, OCH), 3.05 (dd, $J \sim 14.4$ and 9.6 Hz, 1H, NCH_aH_b), 2.70 (t, $J \sim 7.4$ Hz, 2H, CH₂), 2.39 (s, 3H, ArCH₃), 1.62-1.69 (m, 2H, CH₂), 1.26-1.31 (m, 10H, 5 CH₂), 0.87 (t, $J \sim 6.4$ Hz, 3H, CH₃); ¹³C NMR (100 ⁵ MHz, CDCl₃) δ 148.8, 145.9, 144.7, 135.3, 130.2, 127.2, 126.3, 124.4, 123.5, 122.0, 121.6, 117.4, 70.2 (OCH), 51.2 (NCH₂), 45.8 (NCH₂), 31.9, 29.4₄, 29.3₉, 29.3, 25.7, 22.7, 21.7 (ArCH₃), 14.2; HRMS (ESI) Calc. for C₂₆H₃₅N₄O₃S [M+H]⁺ 483.2431, Found: 483.2428.

- ¹⁰ **Compound 22:** Yield 0.189 g (82%); mp 176-178 °C; IR (KBr, cm⁻¹) 3053, 2915, 1578, 1495, 1430, 1358, 1260, 1161, 1062, 931, 810, 762, 668; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, J = 8.4 Hz, 2H, Ar-H), 7.78 (s, 1H, triazole-H), 7.65 (d, J = 8.4 Hz, 1H, Ar-H), 7.50 (d, J = 8.0 Hz, 2H, Ar-H), 7.45 (t, $J \sim$ 7.6 Hz, 1H, Ar-H), 7.36 (t, $J \sim$ 7.6 Hz, 1H, Ar-H), 7.22 (d, J = 8.0 Hz, 2H, Ar-H), 6.78 (dd, J = 8.4 and 1.6 Hz, 1H, Ar-H), 6.68 (br, 1H, Ar-H), 4.56-4.58 (m, 2H, NCH₂), 4.30 (dd, J = 14.4 and 2.4 Hz, 1H, NCH_aH_b), 3.77-3.82 (m, 1H, O-CH), 3.11 (dd, $J \sim$ 14.4 and 9.6 Hz, 1H, NCH_aH_b), 2.28 and 2.37 (2 s, 6H, 2 CH₃); ¹³C NMR
- ²⁰ (100 MHz, CDCl₃) δ 148.1, 145.7, 144.6, 136.7, 135.2, 130.3, 130.2, 129.0, 128.5, 127.3, 125.8, 124.3, 122.7, 120.9, 120.8, 117.7, 70.1 (OCH), 51.5 (NCH₂), 45.9 (NCH₂), 20.9 and 21.7 (2 CH₃); HRMS (ESI) Calc. for C₂₅H₂₄N₄O₃SNa [M+Na]⁺ 483.1467, Found: 483.1465.
- ²⁵ **Compound 23:** Yield 0.181 g (78%); mp 170-173 °C; IR (KBr, cm⁻¹) 3139, 2920, 1583, 1501, 1435, 1353, 1260, 1161, 1057, 932, 816, 673, 531; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, *J* = 8.4 Hz, 1H, Ar-*H*), 7.48 (d, *J* = 8.4 Hz, 2H, Ar-*H*), 7.42 (s, 1H, triazole-*H*), 7.22 (d, *J* = 8.4 Hz, 2H, Ar-*H*), 6.77 (dd, *J* = 8.4 and
- ³⁰ 1.6 Hz, 1H, Ar-*H*), 6.65-6.66 (m, 1H, Ar-*H*), 6.52-6.54 (m, 1H, =C*H*), 4.49 (d, J = 4.8 Hz, 2H, NC*H*₂), 4.26 (dd, J = 14.4 and 2.4 Hz, 1H, NCH_a*H*_b), 3.68-3.73 (m, 1H, OC*H*), 3.03 (dd, $J \sim 14.4$ and 9.6 Hz, 1H, NCH_aH_b), 2.38-2.39 (m, 5H, C*H*₂+ArC*H*₃), 2.28 (s, 3H, C*H*₃), 2.20-2.22 (m, 2H, C*H*₂), 1.67-1.81 (m, 4H, 2 C*H*₂);
- ${}^{35} \, {}^{13}\text{C NMR} \, (100 \text{ MHz, CDCl}_3) \, \delta \, 149.7, \, 145.7, \, 144.5, \, 136.6, \, 135.2, \\ 130.1, \, 127.2, \, 127.0, \, 125.5, \, 124.3, \, 122.5, \, 120.7, \, 119.6, \, 117.6, \\ 70.0 \, (\text{OCH}), \, 51.2 \, (\text{NCH}_2), \, 45.8 \, (\text{NCH}_2), \, 26.3, \, 25.3, \, 22.4, \, 22.2, \\ 21.6, \, 20.9; \, \text{HRMS} \, (\text{ESI}) \, \text{Calc. for} \, \text{C}_{25}\text{H}_{29}\text{N}_4\text{O}_3\text{S} \, [\text{M}+\text{H}]^+ \\ 465.1961, \, \text{Found:} \, 465.1960.$
- ⁴⁰ **Compound 24:** Yield 0.184 g (74%); mp 78-80 °C; IR (KBr, cm⁻¹) 3117, 2920, 2854, 1588, 1501, 1451, 1358, 1260, 1161, 1057, 931, 816, 668, 536; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J = 8.4 Hz, 1H, Ar-H), 7.49 (d, J = 8.4 Hz, 2H, Ar-H), 7.31 (s, 1H, triazole-H), 7.23-7.27 (m, 2H, Ar-H), 6.77 (dd, J = 8.4 and 1.2
- ⁴⁵ Hz, 1H, Ar-*H*), 6.66 (s, 1H, Ar-*H*), 4.48 (d, J = 4.8 Hz, 2H, NCH₂), 4.25 (dd, J = 14.4 and 2.4 Hz, 1H, NCH_aH_b), 3.74-3.76 (m, 1H, OCH), 3.01 (dd, $J \sim 14.4$ and 9.6 Hz, 1H, NCH_aH_b), 2.70 (t, $J \sim 7.8$ Hz, 2H, CH₂), 2.28 and 2.39 (2 s, 6H, 2 ArCH₃), 1.62-1.68 (m, 2H, CH₂), 1.26-1.31 (m, 10H, 5 CH₂), 0.87 (t, J = 6.8
- $_{50}$ Hz, 3H, CH₃); 13 C NMR (100 MHz, CDCl₃) δ 148.8, 145.7, 144.5, 136.6, 135.2, 130.1, 127.2, 124.3, 122.5, 122.0, 120.7, 117.6, 70.0 (OCH), 51.2 (NCH₂), 45.9 (NCH₂), 31.9, 29.4₃, 29.3₉, 29.3, 25.7, 22.7, 21.7, 20.9, 14.2; HRMS (ESI) Calc. for C₂₇H₃₇N₄O₃S [M+H]⁺ 497.2587, Found: 497.2588.
- ⁵⁵ Compound 25: Yield 0.130 g (84%); mp 84-86 °C; IR (KBr, cm⁻¹) 3140, 2948, 2915, 1611, 1573, 1468, 1436, 1260, 1222, 1079, 1047, 915, 756, 690; ¹H NMR (400 MHz, CDCl₃) δ 7.92 (s, 1H, triazole-*H*), 7.83-7.86 (m, 2H, Ar-*H*), 7.45 (t, *J* ~ 7.6 Hz, 2H, Ar-

H), 7.36 (t, $J \sim 7.6$ Hz, 1H, Ar-*H*), 7.02-7.09 (m, 2H, Ar-*H*), 6.86-60 6.92 (m, 2H, Ar-*H*), 4.73-4.82 (m, 3H, *CH*₂+OC*H*), 3.14 (dd, $J \sim 13.2$ and 1.6 Hz, 1H, *CH*_a*H*_b), 2.92 (dd, $J \sim 13.2$ and 7.6 Hz, 1H, *CH*_a*H*_b); ¹³C NMR (100 MHz, CDCl₃) δ 150.3, 148.0, 130.4, 128.9, 128.3, 127.5, 126.1, 125.8, 122.2, 121.0, 118.6, 116.9, 72.5 (OCH), 53.1 (NCH₂), 26.9 (SCH₂); HRMS (ESI) Calc. for 65 C₁₇H₁₆N₃OS [M+H]⁺ 310.1015, Found: 310.1012.

- **Compound 26:** Yield 0.125 g (80 %); mp 98-100 °C; IR (KBr, cm⁻¹) 3140, 2931, 2855, 1737, 1567, 1479, 1447, 1271, 1222, 1074, 1019, 904, 800, 751; ¹H NMR (400 MHz, CDCl₃) δ 7.54 (s, 1H, triazole-*H*), 7.00-7.06 (m, 2H, Ar-*H*), 6.83-6.89 (m, 2H, Ar-
- ⁷⁰ *H*), 6.52-6.57 (m, 1H, cyclohexenyl-*H*), 4.64-4.69 (m, 3H, *CH*₂+OC*H*), 2.85 (dd, *J* = 13.2 and 7.2 Hz, 1H, CH_aH_b), 3.06 (dd, *J* = 13.2 and 1.6 Hz, 1H, *CH*_aH_b), 2.19-2.39 (m, 4H, 2 *CH*₂), 1.65-1.78 (m, 4H, 2 *CH*₂); ¹³C NMR (100 MHz, CDCl₃) δ 150.3, 149.7, 127.5, 127.1, 126.0, 125.3, 122.1, 119.7, 118.5, 116.9,
- $_{75}$ 72.5 (OCH), 52.9 (NCH_2), 26.9 (SCH_2), 26.4, 25.3, 22.4, 22.2; HRMS (ESI) Calc. for $C_{17}H_{20}N_3OS \ \mbox{[M+H]}^+$ 314.1328, Found: 314.1327.
- **Compound 27:** Yield 0.133 g (77%); mp 70-72 °C; IR (KBr, cm⁻¹) 3112, 3057, 2920, 2844, 1573, 1474, 1436, 1293, 1233, 1052,
- ⁸⁰ 997, 866, 734; ¹H NMR (400 MHz, CDCl₃) δ 7.42 (s, 1H, triazole-*H*), 7.01-7.07 (m, 2H, Ar-*H*), 6.83-6.91 (m, 2H, Ar-*H*), 4.65-4.72 (m, 3H, CH₂+OC*H*), 3.10 (dd, *J* ~ 13.2 and 1.6 Hz, 1H, CH_aH_b), 2.86 (dd, *J* ~ 13.2 and 6.4 Hz, 1H, CH_aH_b), 2.72 (t, *J* ~ 7.6 Hz, 2H, CH₂), 1.66-1.68 (m, 2H, CH₂), 1.27-1.32 (m, 10H, 5
- ⁸⁵ CH₂), 0.86-0.89 (m, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃) δ 150.4, 148.8, 127.5, 126.1, 122.2, 122.0, 118.6, 117.0, 72.6 (OCH), 52.9 (NCH₂), 31.9, 29.5, 29.4, 29.3, 27.0 (SCH₂), 25.7, 22.7, 14.2; HRMS (ESI) Calc. for $C_{19}H_{28}N_3OS$ [M+H]⁺ 346.1954, Found: 346.1955.
- ⁹⁰ **Compound 28:** Yield 0.118 g (77%); mp 125-127 °C; IR (KBr, cm⁻¹) 3127, 2940, 2845, 1602, 1582, 1487, 1454, 1248, 1194, 1105, 1082, 905, 766, 694; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (s, 1H, triazole-*H*), 7.90 (dd, *J* = 8.4 and 1.2 Hz, 2H, Ar-*H*), 7.46 (t, *J* ~ 7.6 Hz, 2H, Ar-*H*), 7.37-7.38 (m, 1H, Ar-*H*), 7.05-7.19 (m,
- ⁹⁵ 3H, Ar-*H*), 6.84 (d, J = 8.0 Hz, 1H, Ar-*H*), 4.68 (s, 2H, OCH₂), 4.57-4.62 (m, 2H, CH₂), 4.34-4.35 (m, 1H, OCH), 4.21 (dd, J =12.8 and 1.2 Hz, 1H, CH_aH_b), 3.74 (dd, J = 12.8 and 8.4 Hz, 1H, CH_aH_b); ¹³C NMR (100 MHz, CDCl₃) δ 157.3, 147.9, 132.3, 130.6, 129.6, 129.3, 129.0, 128.3, 125.8, 124.2, 121.1, 121.0, 100 80.7 (OCH₂), 74.3 (OCH), 73.5 (OCH₂), 51.2 (NCH₂); HRMS (ESI) Calc. for C₁₈H₁₇N₃O₂Na [M+Na]⁺ 330.1219, Found:
- 330.1218. **Compound 29:** Yield 0.140 g (83%); mp 140-142 °C; IR (KBr, cm⁻¹) 3106, 2845, 1605, 1582, 1503, 1487, 1454, 1250, 1107,
- ¹⁰⁵ 1032, 907, 822; ¹H NMR (400 MHz, CDCl₃) δ 7.91 (s, 1H, triazole-*H*), 7.81 (d, $J \sim 8.4$ Hz, 2H, Ar-*H*), 7.16-7.21 (m, 2H, Ar-*H*), 7.05 (t, $J \sim 7.6$ Hz, 1H, Ar-*H*), 6.99 (d, J = 8.4 Hz, 2H, Ar-*H*), 6.85 (d, J = 8.0 Hz, 1H, Ar-*H*), 4.68 (s, 2H, OCH₂), 4.56-4.61 (m, 2H, CH₂), 4.34-4.35 (m, 1H, OCH), 4.20 (d, J = 12.8 Hz, 1H,
- ¹¹⁰ CH_aH_b), 3.86 (s, 3H, OCH₃), 3.74 (dd, J = 12.8 and 8.4 Hz, 1H, CH_aH_b); ¹³C NMR (100 MHz, CDCl₃) δ 159.7, 157.4, 147.8, 132.4, 129.6, 129.3, 127.1, 124.2, 123.3, 121.0, 120.3, 114.4, 80.8 (OCH₂), 74.3 (OCH), 73.5 (OCH₂), 55.4 (OCH₃), 51.2 (NCH₂); HRMS (ESI) Calc. for C₁₉H₁₉N₃O₃Na [M+Na]⁺ ¹¹⁵ 360.1324, Found: 360.1326.

Compound 30: Yield 0.127 g (72%); mp 169-171 °C; IR (KBr,

cm⁻¹) 3148, 2853, 1605, 1516, 1464, 1337, 1244, 1109, 1071, 853, 754; ¹H NMR (400 MHz, CDCl₃) δ 8.33 (d, J = 8.8 Hz, 2H, Ar-*H*), 8.16 (s, 1H, triazole-*H*), 8.06 (d, J = 8.8 Hz, 2H, Ar-*H*), 7.18-7.22 (m, 2H, Ar-*H*), 7.06 (t, $J \sim$ 7.2 Hz, 1H, Ar-*H*), 6.82 (d, s J = 8.0 Hz, 1H, Ar-*H*), 4.59-4.72 (m, 4H, 2 CH₂), 4.36-4.37 (m, 1H, OC*H*), 4.23 (dd, $J \sim$ 12.8 and 1.6 Hz, 1H, CH_aH_b), 3.74 (dd, J = 12.8 and 8.4 Hz, 1H, CH_aH_b); ¹³C NMR (400 MHz, CDCl₃) δ 157.2, 147.5, 145.7, 136.8, 132.3, 129.6, 129.4, 126.3, 124.5, 124.4, 122.6, 120.9, 80.5 (OCH₂), 74.3 (OCH), 73.5 (OCH₂),

- ¹⁰ 51.5 (NCH₂); HRMS (ESI) Calc. for $C_{18}H_{16}N_4O_4Na [M+Na]^+$ 375.1070, Found: 375.1068. This compound was crystallized from ethyl acetate/hexane (1:1) mixture at 25 °C. X-ray structure was determined for this compound.
- **Compound 31:** Yield 0.10⁷ g (69%); mp 122-124 °C; IR (KBr, ¹⁵ cm⁻¹) 3148, 2936, 2834, 1580, 1487, 1454, 1267, 1248, 1227, 1121, 1071, 993, 907, 770; ¹H NMR (400 MHz, CDCl₃) δ 7.61 (s, 1H, triazole-*H*), 7.15-7,23 (m, 2H, Ar-*H*), 7.04-7.06 (m, 1H, Ar-*H*), 6.85 (d, *J* = 8.0 Hz, 1H, Ar-*H*), 6.56-6.57 (m, 1H, cyclohexenyl-*H*), 4.66 (s, 2H, OCH₂), 4.50-4.55 (m, 2H, CH₂), ²⁰ 4.28-4.30 (m, 1H, OC*H*), 4.13 (dd, *J* = 12.8 and 1.6 Hz, 1H,
- CH_a*H*_b), 3.70 (dd, *J* = 12.8 and 8.4 Hz, 1H, CH_aH_b), 2.21-2.43 (m, 4H, 2 CH₂), 1.68-1.82 (m, 4H, 2 CH₂); ¹³C NMR (100 MHz, CDCl₃) δ 157.4, 149.6, 132.3, 129.5, 129.3, 127.2, 125.2, 124.2, 121.0, 119.7, 80.7 (OCH₂), 74.3 (OCH), 73.5 (OCH₂), 51.1 ²⁵ (NCH₂), 22.3, 22.5, 25.3 and 26.5 (4 CH₂); HRMS (ESI) Calc.
- for C₁₈H₂₂N₃O₂ [M+H]⁺ 312.1713, Found: 312.1711. **Compound 32:** Yield 0.125 g (65%); mp 166-169 °C; IR (KBr, cm⁻¹) 3332, 3125, 2918, 2856, 1676, 1614, 1563, 1454, 1324, 1242, 1117, 952, 910, 750; ¹H NMR (400 MHz, CDCl₃) δ 8.79 (s,
- ³⁰ 1H, OH), 7.93 (s, 1H, triazole-*H*), 7.85 (d, J = 8.0 Hz, 2H, Ar-*H*), 7.44-7.48 (m, 3H, Ar-*H*), 7.31-7.40 (m, 2H, Ar-*H*), 6.86 (s, 1H, Ar-*H*), 6.84 (d, J = 8.4 Hz, 1H, =C*H*), 6.16-6.23 (m, 1H, =C*H*), 3.93 (d, J = 6.0 Hz, 2H, C*H*₂), 2.37 and 2.84 (2 s, 6H, 2 C*H*₃); ¹³C NMR (100 MHz, CDCl₃) δ 155.5, 148.2, 147.2, 129.8, 129.1,
- $_{35}$ 128.8, 128.2, 127.6, 126.0, 121.9, 119.2, 117.3, 116.7, 115.5, 49.5 (NCH₂), 34.8, 21.7; HRMS (ESI) Calc. for $C_{19}H_{20}N_4O_3SNa$ [M+Na]⁺ 407.1154, Found: 407.1153. This compound was crystallized from dichloromethane/hexane (2:1) mixture at 25 °C. X-ray structure was determined for this compound.
- ⁴⁰ **Compound 33:** (approx. 1:1 diastereomeric ratio), Yield 0.111 g (75%); gummy solid; IR (neat, cm⁻¹) 3134, 2942, 2860, 1734, 1677, 1468, 1441, 1353, 1260, 1162, 1112, 767, 701; ¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1H, triazole-*H*), 7.83-7.86 (m, 5H, Ar-*H*), 7.32-7.45 (m, 6H, Ar-*H*), 5.20 (m, 2H, =C*H*), 3.80-4.84
- ⁴⁵ (m, 11H), 3.42-3.47 (m, 1H), 1.43-2.08 (m, 12H), due to the presence of isomers, number of protons is doubled in the assignment; ¹³C NMR (100 MHz, CDCl₃) δ 149.7, 147.0, 130.6, 128.9, 128.2, 125.8, 121.1, 120.9, 108.8, 107.6, 75.0, 73.3, 72.3, 71.3, 67.6, 66.5, 51.1, 50.2, 29.4, 29.2, 23.8, 23.6, 20.5, due to the
- $_{50}$ presence of isomers, number of carbons is more in the spectrum; HRMS (ESI) Calc. for $C_{17}H_{20}N_3O_2\ \mbox{[M+H]}^+$ 298.1556, Found: 298.1552.

Compound 34: (approx. 1:1 diastereomeric ratio),Yield 0.11 g (71%); gummysolid; IR (neat, cm⁻¹) 3134, 2942, 2860, 1742,

⁵⁵ 1682, 1496, 1447, 1353, 1260, 1167, 1112, 822, 729; ¹H NMR (400 MHz, CDCl₃) δ 7.81 and 7.90 (2 s, 2H, triazole-*H*), 7.71-7.75 (m, 4H, Ar-*H*), 7. 23-7.27 (m, 4H, Ar-*H*), 5.18-5.19 (m, 2H, =C*H*), 3.79-4.82 (m, 11H), 3.41-3.46 (m, 1H), 2.38 (s, 6H), 1.532.11 (m, 12H), due to the presence of isomers, number of protons ⁶⁰ is doubled in the assignment; ¹³C NMR (100 MHz, CDCl₃) δ 149.8, 148.0, 147.8, 147.1, 138.1, 129.6, 127.8, 127.7, 125.7, 120.8, 120.5, 108.9, 107.6, 75.0, 73.3, 72.3, 71.3, 69.6, 67.7, 66.6, 51.1, 50.2, 29.5, 29.3, 23.8, 23.6, 21.4, 20.5, due to the presence of isomers, number of carbons is more in the spectrum; ⁶⁵ HRMS (ESI) Calc. for C₁₈H₂₂N₃O₂ [M+H]⁺ 312.1713, Found:

312.1712. **Compound 35:** (approx. 1:1 diastereomeric ratio), Yield 0.118 g (69%); mp 142-145 °C; IR (KBr, cm⁻¹) 3151, 2948, 2860, 1731, 1682, 1605, 1507, 1458, 1337, 1156, 1112, 855, 756; ¹H NMR ⁷⁰ (400 MHz, CDCl₃) δ 8.29-8.31 (m, 4H, Ar-*H*), 8.10 (s, 1H,

- ⁷⁰ (400 MHz, CDCl₃) δ 8.29-8.31 (m, 4H, AF-*H*), 8.10 (s, 1H, triazole-*H*), 8.01-8.04 (m, 5H, Ar-*H*), 5.20-5.21 (m, 2H, =C*H*), 3.83-4.90 (m, 11H), 3.45-3.48 (m, 1H), 1.53-2.12 (m, 12H), due to the presence of isomers, number of protons is doubled in the assignment; ¹³C NMR (100 MHz, CDCl₃) δ 149.6, 147.3, 147.0,
- $_{75}$ 145.8, 145.6, 136.9, 126.2, 124.3, 122.6, 122.3, 109.0, 107.9, 74.9, 73.2, 72.4, 71.3, 67.6, 66.6, 51.3, 50.5, 29.4, 29.2, 23.8, 23.5, 20.5, due to the presence of isomers, number of carbons is more in the spectrum; HRMS (ESI) Calc. for $C_{17}H_{19}N_3O_4$ $[M+H]^+$ 343.1407, Found: 343.1404.
- ⁸⁰ Compound 36: Yield 0.104 g (56 %); Mp 139-141 °C; IR (KBr, cm⁻¹) 3364, 3134, 1567, 1479, 1447, 1288, 1233, 1118, 1052, 958, 745, 690; ¹H NMR (400 MHz, CDCl₃) δ 7.91 (s, 1H, triazole-*H*), 7.73 (d, *J* ~ 7.6 Hz, 2H, Ar-*H*), 7.55 (d, *J* = 8.0 Hz, 1H, Ar-*H*), 7.39 (t, *J* ~ 7.6 Hz, 2H, Ar-*H*), 7.32 (t, *J* ~ 7.6 Hz, 1H,
- ⁸⁵ Ar-*H*), 7.24-7.28 (m, 1H, Ar-*H*), 6.87-6.91 (m, 2H, Ar-*H*), 4.79 (dd, J = 14.0 and 3.6 Hz, 1H, CH_aH_b), 4.65 (dd, J = 14.0 and 6.4 Hz, 1H, CH_aH_b), 4.58-4.59 (m, 1H, OCH), 4.02-4.07 (m, 2H, CH₂),3.77 (br, 1H, OH); ¹³C NMR(400 MHz, CDCl₃) δ 154.4, 147.7, 133.5, 130.3, 128.9, 128.8, 128.3, 125.7, 123.0, 121.6, ⁹⁰ 113.9, 112.4, 70.0, 68.8, 53.0; HRMS (ESI) Calc. for C₁₇H₁₇BrN₃O₂ [M+H]⁺ 375.0505 and 376.0663, Found: 375.0508

and 376.0491. General procedure for the synthesis compounds **37-41**:

An oven-dried Schlenk tube with a magnetic stirring bar was ⁹⁵ charged with benzotriazole (0.5 mmol) and epoxide (0.5 mmol) and then heated at 100 °C for 2 h. Later, CuI (10 mol%), picolinic acid (20 mol%), cesium carbonate (3.0 equiv.), and toluene (1 mL) were added under nitrogen atmosphere and the contents heated at 120 °C (oil bath temperature) for 12 h. The mixture was ¹⁰⁰ then cooled to ambient temperature, diluted with 2-3 mL of ethyl acetate, passed through a plug of celite, and then washed with 20-30 mL of ethyl acetate. The organic layer was evaporated and the residue purified by column chromatography on silica gel by using hexane/ethyl acetate (75/25) as eluent to afford the desired ¹⁰⁵ product. Compounds **37-40** were synthesised following the molar quantities mentioned above in each case. Compound **41** was isolated without addition of copper-catalyst.

Compound 37: Yield 0.99 g (74 %); Mp 128-130 °C; IR (KBr, cm⁻¹) 1594, 1506, 1451, 1342, 1265, 1194, 1040, 914, 832, 750; ¹¹⁰ ¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, *J* = 8.4Hz, 1H, Ar-*H*),

¹¹⁰ H NMR (400 MHZ, CDCl₃) δ 8.08 (d, J = 8.4HZ, 1H, AF-*H*), 7.50-7.59 (m, 2H, Ar-*H*), 7.38-7.42 (m, 1H, Ar-*H*), 6.83-6.93 (m, 4H, Ar-*H*), 4.96 (d, J = 5.6 Hz, 2H, CH₂), 4.74-4.78 (m, 1H, OC*H*), 4.36 (dd, $J \sim 12.0$ and 2.4 Hz, 1H, CH_aH_b), 3.96 (dd, J =12.0 and 6.0 Hz, 1H, CH_aH_b); ¹³C NMR (100 MHz, CDCl₃) δ ¹¹⁵ 145.9, 142.8, 142.0, 133.8, 127.8, 124.2, 122.1, 120.0, 117.5, 117.4, 109.9, 71.9, 65.0, 48.1; HRMS (ESI) Calc. for $C_{15}H_{14}N_3O_2$ [M+H]⁺ 268.1087, Found: 268.1088.

Compound 38: Yield 0.124 g (77 %); Mp 115-116 °C; IR (KBr, cm⁻¹) 2953, 2871, 1595, 1452, 1321, 1266, 1058, 915, 822, 745; ⁵ ¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, J = 8.4 Hz, 1H, Ar-*H*), 7.48-7.54 (m, 2H, Ar-*H*), 7.38-7.42 (m, 1H, Ar-*H*), 6.91 (dd, $J \sim$ 8.4 and 2.4 Hz, 1H, Ar-*H*), 6.84-6.86 (m, 2H, Ar-*H*), 4.95 (d, J = 6.0 Hz, 2H, CH₂), 4.73-4.78 (m, 1H, OCH), 4.33 (dd, $J \sim$ 11.6 and 2.4 Hz, 1H, CH_aH_b), 3.98 (dd, J = 11.6 and 5.6 Hz, 1H,

- ¹⁰ CH_aH_b), 1.28 (s, 9H, C(CH_3)₃); ¹³C NMR (100 MHz, CDCl₃) δ 146.0, 145.6, 141.3, 142.4, 133.9, 127.8, 124.2, 120.1, 119.0, 116.8, 114.7, 109.9, 72.0, 65.1, 48.0, 34.3, 31.5; HRMS (ESI) Calc. for C₁₉H₂₂N₃O₂ [M+H]⁺ 324.1713, Found: 324.1711.
- **Compound 39:** Yield 0.108 g (73 %); Mp 119-121 °C; IR (KBr, 15 cm⁻¹) 2921, 1605, 1496, 1447, 1321, 1211, 1151, 1118, 1063, 904, 833, 751; ¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, J = 8.4 Hz, 1H, Ar-*H*), 7.59 (d, J = 8.4 Hz, 1H, Ar-*H*), 7.52 (t, J = 7.6 Hz, 1H, Ar-*H*), 7.40 (t, J = 7.6 Hz, 1H, Ar-*H*), 6.56 (s, 1H, Ar-*H*), 6.50 (s, 1H, Ar-*H*), 4.94 (d, J = 5.6 Hz, 2H, CH₂), 4.70-4.72 (m, 20 1H, OC*H*), 4.34 (dd, J = 11.6 and 2.0 Hz, 1H, CH_aH_b), 3.94 (dd, J = 11.6 and 6.0 Hz, 1H, CH_aH_b), 2.17 and 2.21 (2 s, 6H, 2 CH₃); ¹³C NMR (100 MHz, CDCl₃) δ 146.0, 141.5, 138.8, 133.9, 130.9, 127.8, 126.7, 124.2, 124.1, 120.0, 115.4, 110.0, 71.9, 65.1, 48.2, 20.7, 15.4, HRMS (ESI) Calc. for C₁₇H₁₈N₃O₂ [M+H]⁺ 296.1400, 25 Found: 296.1404.
- **Compound 40:** Yield 0.170 g (81 %); Mp 142-144 °C; IR (KBr, cm⁻¹) 3047, 2915, 1595, 1490, 1447, 1348, 1255, 1162, 1068, 915, 849, 750; ¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, J = 8.0 Hz, 1H, Ar-*H*), 7.78 (d, J = 8.0 Hz, 1H, Ar-*H*), 7.51-7.53 (m, 2H, Ar-³⁰ *H*), 7.38-7.43 (m, 3H, Ar-*H*), 7.03-7.10 (m, 3H, Ar-*H*), 6.94 (t, J = 7.6 Hz, 1H, Ar-*H*), 6.77 (d, J = 8.4 Hz, 1H, Ar-*H*), 4.80 (d, J =
- 4.8 Hz, 2H, CH₂), 4.36 (dd, $J \sim 14.4$ and 2.0 Hz, 1H, CH_aH_b), 3.76-3.78 (m, 1H, OCH), 3.17 (dd, J = 14.4 and 10.0 Hz, 1H, CH_aH_b), 2.32 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃) δ 146.0, 144.6, 125.2, 122.7, 127.8, 127.1, 126.4, 124.8, 124.2,
- **Compound 41:** Yield 0.182 g (92 %); Mp 138-140 °C; IR (KBr, ⁴⁰ cm⁻¹) 3238, 1584, 1474, 1463, 1441, 1278, 1249, 1118, 1058, 751; ¹H NMR (400 MHz, CDCl₃) δ 7.91 (d, *J* = 8.4 Hz, 1H, Ar-*H*), 7.78 (d, *J* = 7.6 Hz, 1H, Ar-*H*), 7.69 (d, *J* = 8.4 Hz, 1H, Ar-*H*), 7.46 (t, *J* ~ 7.6 Hz, 1H, Ar-*H*), 7.29-7.33 (m, 2H, Ar-*H*), 6.74-6.80 (m, 2H, Ar-*H*), 5.03 (dd, *J* ~ 12.0 and 4.0 Hz, 1H, CH_aH_b), 45 4.92 (dd, *J* ~ 14.4 and 6.8 Hz, 1H, CH_aH_b), 4.67-4.68 (m, 1H, OC*H*), 4.06-4.09 (m, 2H, CH₂), 3.75 (d, *J* = 5.6 Hz, 1H, O*H*); ¹³C NMR (100 MHz, CDCl₃) δ 156.4, 145.5, 139.4, 133.9, 129.8, 127.7, 124.2, 123.5, 119.7, 112.5, 110.1, 86.6 (CI), 69.9, 69.2, 50.8; HRMS (ESI) Calc. for C₁₅H₁₅IN₃O₂ [M+H]⁺ 396.0210, ⁵⁰ Found: 396.0205.

Single crystal X-ray data were collected on a Bruker AXS-SMART or OXFORD diffractometer using Mo-K_{α} (λ = 0.71073 Å) radiation. The structures were solved by direct methods and ⁵⁵ refined by full-matrix least squares method using standard procedures.¹³ Absorption corrections were done using SADABS program, where applicable. In general, all non-hydrogen atoms were refined anisotropically; hydrogen atoms were fixed by geometry or located by a Difference Fourier map and refined 60 isotropically.

Crystal data

16: C₁₇H₁₄ClN₃O₂, *M* = 327.76, Monoclinic, Space group *P2(1)/c*, *a* = 11.1770(11), *b* = 5.4737(4), *c* = 25.780(3) Å, β = 100.299(9)°, *V* = 1551.8(3) Å³, *Z* = 4, μ = 0.259 mm⁻¹, data/restraints/parameters: 2742 / 0 / 208, R indices (*I* > 2σ(*I*)): R1 = 0.0599, *wR*2 (all data) = 0.1575. CCDC No. 929370. **20:** C₂₄H₂₆N₄O₃S, *M* = 450.55, Monoclinic, Space group *P2(1)/n*, *a* = 8.5356(5), *b* = 10.9149(6), *c* = 24.3049(16) Å, β = 70 95.720(6)°, *V* = 2253.1(2) Å³, *Z* = 4, μ = 0.178 mm⁻¹,

data/restraints/parameters: 3948 / 0 / 290, R indices $(I > 2\sigma(I))$: R1 = 0.0699, wR2 (all data) = 0.1956. CCDC No. 929371. **30:** C₁₈H₁₆N₄O₄, M = 352.35, Triclinic, Space group P-1, a =

6.0255(6), b = 10.3665(11), c = 12.6263(14) Å, $a = 92.903(9)^\circ$, β 75 = 97.168(8)°, $\gamma = 94.666(8)^\circ$, V = 840.11(15) Å³, Z = 2, $\mu = 0.101$ mm⁻¹, data/restraints/parameters: 2948/ 0/235, R indices (I >

- $2\sigma(I)$: R1 = 0.0549, *wR2* (all data) = 0.1525. CCDC No. 929372.
- **32:** $C_{19}H_{20}N_4O_3S$, M = 384.45, Monoclinic, Space group P2(1)/c, a = 8.4958(6), b = 11.6503(8), c = 18.9628(14) Å, $\beta =$
- ⁸⁰ 94.116(1)°, V = 1872.1(2) Å³, Z = 4, $\mu = 0.201$ mm⁻¹, data/restraints/parameters: 3694 / 0 / 247, R indices ($I > 2\sigma(I)$): R1 = 0.0419, wR2 (all data) = 0.1269. CCDC No. 929373.

Acknowledgment

We thank Department of Science and Technology (DST, New ⁸⁵ Delhi) for financial support and Single Crystal X-ray diffractometer facility, and the University Grants Commission (UGC, New Delhi) for equipment under UPE and CAS programs. MNR thank Council of Scientific and Industrial Research (CSIR, New Delhi) for fellowship. KCK thanks DST for the J. C. Bose ⁹⁰ fellowship.

Notes and references

115

- ^a School of Chemistry, University of Hyderabad, Hyderabad 500 046, A. P., India. Fax: (+91)-40-23012460; Tel: (+91)-40-231348560; E-mail: <u>kckssc@uohyd.ernet.in, kckssc@yahoo.com</u>
- ⁹⁵ † Electronic Supplementary Information (ESI) available [details on the synthesis of precursors **1a-1k** and **2a-2k**, ¹H and ¹³C NMR spectra, and CIF files. See DOI: 10.1039/b000000x/
- (a) J. Shen, R. Woodward, J. P. Kedenburg, X. Liu, L. Fang, D. Sun and P. G. Wang, *J. Med. Chem.*, 2008, **51**, 7417. (b) K. Sivakumar, F. Xie, B. M. Cash, S. Long, H. N. Barnhill and Q. Wang, *Org. Lett.*, 2004, **6**, 4603; (c) G. Biagi, I. Giorgi, O. Livi, V. Scartoni, L. Betti, G. Giannaccini and M. L. Trincavelli, *Eur. J. Med. Chem.*, 2002, **37**, 565; (d) M. Meldal and C. W. Tornøe, *Chem. Rev.*, 2008, **108**, 2952;
 (e) S. G. Agalave, S. R. Maujan and V. S. Pore, *Chem. Asian J.*,
- 2011, 6, 2696.
 P(III) azides, though, react in a manner different from organic azides. See: S. Kumaraswamy, P. Kommana, N. Satish Kumar and K. C. Kumara Swamy, *Chem. Commun.*, 2002, 40 (and the references cited therein); (b) M. Chakravarty, N. N. Bhuvan Kumar, K. V. Sajna and K. C. Kumara Swamy, *Eur. J. Org. Chem.*, 2008, 4500; (c) K. P. Kaliappan, P. Kalanidhi and S. Mahapatra, *Synlett* 2009, 13, 2162.
 - (a) G. Evano, N. Blanchard and M. Toumi, *Chem. Rev.*, 2008, 108, 3054; (b) A. W. Thomas and S. V. Ley, *Angew. Chem. Int. Ed.*, 2003, 42, 5400; (c) I. P. Beletskaya and A. V. Cheprakov, *Coord. Chem. Rev.*, 2004, 248, 2337; (d) Y. Liu and J.-P. Wan, *Chem. Asian J.*, 2012, 7, 1488; (e) F. Monnier and M. Taillefer, *Angew. Chem. Int.*

Ed., 2009, **48**, 6954; (f) Y. Liu and J.-P. Wan, *Org. Biomol. Chem.*, 2011, **9**, 6873; (g) J. E. R. Sadig and M. C. Willis, *Synthesis*, 2011, 0001; (h) Y.-J. Chen and H.-H. Chen, *Org. Lett.*, 2006, **8**, 5609.

- (a) S.-I. Kuwabe, K. E. Torraca and S. L. Buchwald, J. Am. Chem. Soc., 2001, 123, 12202. (b) Q. Shelby, N. Kataoka, G. Mann and J. Hartwig, J. Am. Chem. Soc., 2000, 122, 10718. (c) A. V. Vorogushin, X. Huang and S. L. Buchwald, J. Am. Chem. Soc., 2005, 127, 8146.
 (d) G. Mann and J. Hartwig, J. Am. Chem. Soc., 1996, 118, 13109;
 (e) X. Wu, B. P. Fors and S. L. Buchwald, Angew. Chem. Int. Ed., 2011, 50, 9943;
- (a) A. Shafir, P. A. Lichtor and S. L. Buchwald, J. Am. Chem. Soc., 2007, **129**, 349; (b) X. Lv and W. Bao, J. Org. Chem., 2007, **72**, 3863; (c) R. A. Altman, A. Shafir, A. Choi, P. A. Lichtor and S. L. Buchwald, J. Org. Chem., 2008, **73**, 284; (d) S. Jammi, S. Sakthivel,
- L. Rout, T. Mukherjee, S. Mandal, R. Mitra, P. Saha and T. Punniyamurthy, J. Org. Chem., 2009, 74, 1971; (e) D. Maiti and S. L. Buchwald, J. Org. Chem., 2010, 75, 1791; (f) S. Bhadra, L. Adak, S. Samanta, A. K. M. M. Isalam, M. Mukherjee and B. C. Ranu, J. Org. Chem., 2010, 75, 8533; (g) M. Wolter, G. Nordmann, G. E. Job and
- 20 S. L. Buchwald, Org. Lett., 2002, 4, 973; (h) L. Rout, T. K. Sen and T. Punniyamurthy, Angew. Chem. Int. Ed., 2007, 46, 5583.
- (a) Y. Liu and W. Bao, Org. Biomol. Chem., 2010, 8, 2700;
 (b) K. Swapna, S. N. Murthy, M. T. Jyothi and Y. V. D. Nageswar, Org. Biomol. Chem., 2011, 9, 5978;
 (c) R. K. Rao, A. B. Naidu and G.
- Sekar, Org. Lett., 2009, **11**, 1923; (d) A. B. Naidu, D. Ganapathy and G. Sekar, Synthesis, 2010, 3509; (e) A. S. Das, G. Pal, P. Bhattacharyya, A. K. Ghosh, D. Mukherjee and D. Bandyopadhyay, Tetrahedron Lett., 2012, **53**, 7060. (f) X. Xu, L. Liang, J. Liu, J. Yang, L. Mai, Y. Li, Tetrahedron Lett., 2009, **50**, 57. (g) W. Bao, Y.
 Liu, X. Lv, W. Qian, Org. Lett. 2008, **10**, 3899.
- (a) A. Sateesh Kumar, P. V. Amulya Rao and R. Nagarajan, *Synthesis*, 2011, 3877; (b) M. E. Garcia-Rubino, M. C. Nunez, M. A. Gallo and J. M. Campos, *RSC Advances*, 2012, **2**, 12631; (c) R. Paul and T. Punniyamurthy, *RSC Advances*, 2012, **2**, 7057.
- 8. (a) R. Zhou, G. Luo and A. G. Ewing, J. Neurosci., 1994, 14, 2402; (b)
 M. W. Baines, D. B. Cobb, R. J. Eden, R. Fielden, J. N. Gardner, A.M. Roe, W. Tertiuk and G. L. Willey, J. Med. Chem., 1965, 8, 81;
 (c) J. Augstein, S. M. Green, A. M. Monro, G. W. H. Potter, C. R. Worthing and T. I. Wrigley, J. Med. Chem., 1965, 8, 446; (d) R.
- Howe, B. S. Rao and M. S. Chodnekar, J. Med. Chem., 1970, 13, 169; (e) W. L. Nelson and J. E. Wennerstrom, J. Med. Chem., 1977, 20, 880; (f) E. N. Koini, P. Papazafiri, A. Vassilopoulos, M. Koufaki, Z. Horváth, I. Konez, L. Virág, G. J. Papp, A. Varró and T. Calogeropoulou, J. Med. Chem., 2009, 52, 2328; (g) A. Conejo-
- 45 Garcia, M. E. Garcia-Rubino, J. A. Marchal, M. C. Nunez, A. Ramirez, S, Cimino, M. A. Garcia, A. Aranega, M. A. Gallo and J. M. Campos, *Eur. J. Med. Chem.*, 2011, **46**, 3795; (h) Z. J. Song, A. O. King, M. S. Waters, F. Lang, D. Zewge, M. Bio, J. L. Jr. Leazer, G. Javadi, A. Kassim, D. M. Tschaen, R. A. Reamer, T. Rosner, J. R. Chilardi, D. J. McHard, P. D. Valenter, **4**, 2004.
- Chilenski, D. J. Mathre, R. P. Volante and R. Tillyer, *PNAS*, 2004, 101, 5776.
 P. P. Pama Suresh and K. C. Kumara Swamy. *Tetrahadron Lett.* 2009.
- 9 (a) R. Rama Suresh and K. C. Kumara Swamy, *Tetrahedron Lett.*, 2009,
 50, 6004; (b) M. Phani Pavan, M. Chakravarty and K. C. Kumara Swamy, *Eur. J. Org. Chem.*, 2009, 5927; (c) V. Srinivas, E.
- Balaraman, K. V. Sajna and K. C. Kumara Swamy, *Eur. J. Org. Chem.*, 2011, 4222; (d) R. Kotikalapudi and K. C. Kumra Swamy, *Tetrahedron Lett.*, 2012, **53**, 3831; (e) R. Rama Suresh and K. C. Kumara Swamy, *J. Org. Chem.*, 2012, **77**, 6959.
- 10. M. Nagarjuna Reddy and K. C. Kumara Swamy, *Eur. J. Org. Chem.*, 2011, 2012.
- 11. D. Albanese, D. Landini, V. Lupi, M. Penso and D. Scaletti, *J. Mol. Catal. A: Chem.*, 2008, **288**, 28.
- S. Menichetti, M. C. Aversa, F. Cimino, A. Contini, C. Viglianisi and A. Tomaino, Org. Biomol. Chem., 2005, 3, 3066.
- 65 13. B. T. Worrell, J. A. Malik and V. V. Fokin, Science, 2013, 340, 457.
- 14.A. K. Verma, T. Kesharani, J. Singh, V. Tandon and R. C. Larock, *Angew. Chem. Int. Ed.*, 2009, **48**, 1138.
- 15 E. Sperotto, G. P. M. Van Klink, G. van Koten, J. G. de Vries, *Dalton Trans.*, 2010, **39**, 10338.
- 70 16.(a) G. O. Jones, P. Liu, K. N. Houk and S. L. Buchwald, J. Am. Chem. Soc., 2010, **132**, 6205; (b) J. W. Tye, Z. Weng, R. Giri and J. F.

Hartwig, *Angew. Chem. Int. Ed.*, 2010, **49**, 2185; (c) E. Sperotto, G. P. M. van Klink, G. van Koten and J. G. de Vries, *Dalton. Trans.*, 2010, **39**, 10338.

 75 17. (a) G. M. Sheldrick, SADABS, Siemens Area Detector Absorption Correction, University of Göttingen, Germany, 1996; (b) G. M. Sheldrick, SHELX–97 A program for crystal structure solution and refinement, University of Göttingen, 1997; (c) G. M. Sheldrick, SHELXTL NT Crystal Structure Analysis Package, Bruker AXS, Analytical X-ray System, WI, USA, 1999, version 5.10.